Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06656559
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-23
Brief Title:
Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation ERCP-RFA Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation ERCP-RFA Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma A Prospective Single-Arm Single-Center Phase II Clinical Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The sequential treatment strategy of ERCP-RFA combined with envafolimab and surufatinib proposed in this study aims to maximally inhibit the progression of unresectable biliary tract tumors through the combined application of multiple therapeutic modalities ERCP-RFA as a local treatment first reduces the tumor burden and alleviates biliary obstruction through physical ablation Subsequently Envafolimab enables the body to more effectively identify and attack the remaining tumor cells by activating the immune system Finally Surufatinib as a targeted drug further controls the growth and spread of tumors by inhibiting tumor angiogenesis and cell proliferation The potential advantage of this combined treatment lies in the complementary effects of different therapeutic modalities
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None